The rational reasons for selection of CP are as follows: (1) its anti-tumor activity has been extensively examined, particularly in clinical trials [24,25,26], and (2) the molecular mechanisms and pathways involved in CP resistance/sensitivity have been explored [27,28,29]. The gene discussed is CP; the disease is neoplasm.